SinoMab BioScience Limited
HKEX:3681.HK
1.07 (HKD) • At close November 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Assets: | |||||||
| Current Assets: | |||||||
| Cash & Cash Equivalents
| 203.664 | 345.712 | 562.983 | 810.37 | 1,200.868 | 41.512 | 66.096 |
| Short Term Investments
| 30.993 | 46.197 | 26.547 | 12.774 | 6.489 | 1.103 | 46.84 |
| Cash and Short Term Investments
| 237.528 | 422.385 | 589.53 | 916.202 | 1,200.868 | 41.512 | 112.936 |
| Net Receivables
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets
| 32.655 | 70.905 | 6.155 | 18.152 | 7.685 | 8.758 | 13.89 |
| Total Current Assets
| 270.183 | 447.093 | 595.685 | 934.354 | 1,215.042 | 50.27 | 126.826 |
| Non-Current Assets: | |||||||
| Property, Plant & Equipment, Net
| 536.774 | 485.817 | 356.207 | 145.923 | 69.123 | 38.549 | 34.81 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 1.844 | 2.595 | 1.921 | 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 1.844 | 2.595 | 1.921 | 0 | 0 | 0 | 0 |
| Long Term Investments
| 0 | 0 | 26.933 | 31.897 | 0 | 0 | 0 |
| Tax Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 38.985 | -488.412 | -385.061 | -177.82 | 0 | 0 | 0 |
| Total Non-Current Assets
| 577.603 | 488.412 | 385.061 | 177.82 | 69.123 | 38.549 | 34.81 |
| Total Assets
| 847.786 | 1,008.348 | 1,041.655 | 1,129.523 | 1,284.165 | 88.819 | 161.636 |
| Liabilities & Equity: | |||||||
| Current Liabilities: | |||||||
| Account Payables
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short Term Debt
| 71.251 | 45.801 | 12.394 | 14.13 | 8.04 | 27.273 | 184.299 |
| Tax Payables
| 0.494 | 0.569 | 0.397 | 0.167 | 0.029 | 0.019 | 0.021 |
| Deferred Revenue
| -101.095 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities
| 100.901 | 141.021 | 85.573 | 44.507 | 98.606 | 1.127 | 0.587 |
| Total Current Liabilities
| 172.646 | 187.391 | 98.364 | 58.804 | 106.675 | 28.419 | 184.907 |
| Non-Current Liabilities: | |||||||
| Long Term Debt
| 379.557 | 311.382 | 263.065 | 83.708 | 45.574 | 32.994 | 27.681 |
| Deferred Revenue Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 0 | -73.024 | -69.288 | -28.247 | 0 | 0 | 0 |
| Total Non-Current Liabilities
| 379.557 | 238.358 | 193.777 | 55.461 | 45.574 | 32.994 | 27.681 |
| Total Liabilities
| 552.203 | 498.773 | 361.429 | 142.512 | 152.249 | 61.413 | 212.588 |
| Equity: | |||||||
| Preferred Stock
| 0 | 0 | 35.939 | 17.348 | 0 | 275.885 | 192.275 |
| Common Stock
| 1,725.211 | 1,725.211 | 1,679.126 | 1,679.126 | 1,679.126 | 301.532 | 152.532 |
| Retained Earnings
| 0 | -1,247.119 | -962.961 | -674.767 | -552.167 | -275.885 | -192.275 |
| Accumulated Other Comprehensive Income/Loss
| 60.602 | 31.483 | -35.939 | -17.348 | 4.957 | -18.579 | -13.019 |
| Other Total Stockholders Equity
| -1,490.23 | 0 | -0 | -0 | 0 | -551.77 | -11.209 |
| Total Shareholders Equity
| 295.583 | 509.575 | 680.226 | 987.011 | 1,131.916 | 27.406 | -50.952 |
| Total Equity
| 295.583 | 509.575 | 680.226 | 987.011 | 1,131.916 | 27.406 | -50.952 |
| Total Liabilities & Shareholders Equity
| 847.786 | 1,008.348 | 1,041.655 | 1,129.523 | 1,284.165 | 88.819 | 161.636 |